The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
Abstract
Purpose: This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods: Fresh frozen tumor tissue from 188 patients with stage I to IV CRC undergoing surgery was analyzed using Agilent 44K oligonucleotide arrays. Median follow-up time was 65.1 months, and the majority of patients (83.6%) did not receive adjuvant chemotherapy. A nearest mean classifier was developed using a cross-validation procedure to score all genes for their association with 5-year distant metastasis–free survival. Results: An optimal set of 18 genes was identified and used to construct a prognostic classifier (ColoPrint). The signature was validated on an independent set of 206 samples from patients with stage I, II, and III CRC. The signature classified 60% of patients as low risk and 40% as high risk. Five-year relapse-free survival rates were 87.6% (95% CI, 81.5% to 93.7%) and 67.2% (95% CI, 55.4% to 79.0%) for low- and high-risk patients, respectively, with a hazard ratio (HR) of 2.5 (95% CI, 1.33 to 4.73; P = .005). In multivariate analysis, the signature remained one of the most significant prognostic factors, with an HR of 2.69 (95% CI, 1.41 to 5.14; P = .003). In patients with stage II CRC, the signature had an HR of 3.34 (P = .017) and was superior to American Society of Clinical Oncology criteria in assessing the risk of cancer recurrence without prescreening for microsatellite instability (MSI). Conclusion: ColoPrint significantly improves the prognostic accuracy of pathologic factors and MSI in patients with stage II and III CRC and facilitates the identification of patients with stage II disease who may be safely managed without chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Garman, K. S., Acharya, C. R., Edelman, E. J., Grade, M., Gaedcke, J., Sud, S., Barry, W. T., Diehl, A. M., Provenzale, D., Ginsburg, G. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806674105 · Cited by 85
RetractedGene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,599
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., & Haller, D. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.062 · Cited by 1,149
Prediction of cancer outcome with microarrays: a multiple random validation strategy
Michiels, S., Koscielny, S., & Hill, C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17866-0 · Cited by 1,025
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Outcome signature genes in breast cancer: is there a unique set?
Ein-Dor, L., Kela, I., Getz, G., Givol, D., & Domany, E. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth469 · Cited by 802
Converting a breast cancer microarray signature into a high-throughput diagnostic test
Glas, A. M., Floore, A., Delahaye, L. J., Witteveen, A. T., Pover, R. C., Bakx, N., Lahti-Domenici, J. S., Bruinsma, T. J., Warmoes, M. O., Bernards, R., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-278 · Cited by 494
Self-citationGene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer
Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., McLeod, H. L., & Atkins, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.186 · Cited by 460
Microarray Analysis and Tumor Classification
Quackenbush, J. (2006) · New England Journal of Medicine · doi:10.1056/nejmra042342 · Cited by 455
Molecular Staging for Survival Prediction of Colorectal Cancer Patients
Eschrich, S., Yang, I., Bloom, G., Kwong, K. Y., Boulware, D., Cantor, A., Coppola, D., Kruhøffer, M., Aaltonen, L., Orntoft, T. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.695 · Cited by 348
Kaiser, S., Park, Y.-K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., Freudenberg, J., Chen, X., Haigis, K., Jegga, A. G., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r131 · Cited by 338
Bertucci, F., Salas, S., Eysteries, S., Nasser, V., Finetti, P., Ginestier, C., Charafe-Jauffret, E., Loriod, B., Bachelart, L., Montfort, J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207262 · Cited by 326
Poynter, J. N., Siegmund, K. D., Weisenberger, D. J., Long, T. I., Thibodeau, S. N., Lindor, N., Young, J., Jenkins, M. A., Hopper, J. L., Baron, J. A., et al. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0512 · Cited by 229
Stage II Colon Cancer Prognosis Prediction by Tumor Gene Expression Profiling
Barrier, A., Boelle, P.-Y., Roser, F., Gregg, J., Tse, C., Brault, D., Lacaine, F., Houry, S., Huguier, M., Franc, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0229 · Cited by 214
Morris, E. J. A., Maughan, N., Forman, D., & Quirke, P. (2007) · Gut · doi:10.1136/gut.2006.116830 · Cited by 136
Lin, Y.-H., Friederichs, J., Black, M. A., Mages, J., Rosenberg, R., Guilford, P., Phillips, V., Thompson-Fawcett, M. W., Kasabov, N. K., Toro, T. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2734 · Cited by 131
Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Tsuruta, D., Kobayashi, H., Imanishi, H., Sugawara, K., Ishii, M., & Jones, J. C. R. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132834 · Cited by 120
Kerr, D., Gray, R. G., Quirke, P., Watson, D., Yothers, G., Lavery, I. C., Lee, M., O’Connell, M. J., Shak, S., Wolmark, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4000 · Cited by 111
Self-citationPrognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling
Barrier, A. J., Roser, F., Boëlle, P., Franc, B., Tsé, C., Brault, D., LACAINE, F., Houry, S., Callard, P., Penna, C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210060 · Cited by 63
Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer
Jiang, Y., Casey, G., Lavery, I. C., Zhang, Y., Talantov, D., McGreevy, M., Skacel, M., Manilich, E. A., Mazumder, A., Atkins, D., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080011 · Cited by 62
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer?
Sobrero, A. F., & Köhne, C.-H. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70727-6 · Cited by 47
Cutsem, E. V., Oliveira, J., & Kataja, V. V. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi803 · Cited by 19
Cited by
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citation
Metadata
- Authors
- Salazar, R., Roepman, P., Capella, G., Moreno, V., Simon, I., Dreezen, C., Lopez-Doriga, A., Santos, C., Marijnen, C., Westerga, J., Bruin, S., Kerr, D., Kuppen, P., van de Velde, C., Morreau, H., Van Velthuysen, L., Glas, A. M., Van't Veer, L. J., & Tollenaar, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-01
- Volume
- 29
- Issue
- 1
- Pages
- 17-24
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165389801
- Cited by
- 537
- References
- 28
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.